|
| |
|
|
소아에서 수두 예방 접종아와 감염 면역아의 수두 특이 IgG 황체가에 대한 연구
파일 
소아에서 수두 예방 접종아와 감염 면역아의 수두 특이 IgG 황체가에 대한 연구.hwp
[Size :
60 Kbyte
]
소아에서 수두 예방 접종아와 감염 면역아의 수두 특이 IgG 황체가에 대한 연구.hwp
[Size :
60 Kbyte
]
분량 7 Page
가격 1,000 원
×
링크주소가 복사 되었습니다.
원하는 곳에 붙혀넣기 하세요
원하는 곳에 붙혀넣기 하세요
카트
|
다운받기
|
 네이버 ID로 다운 받기  카카오 ID로 다운 받기  구글 ID로 다운 받기  페이스북 ID로 다운 받기 |
뒤로
|
자료설명
수두는 신생아를 포함하여 어느 연령에서나 발생하는 질환으로 호흡기나 직접적인 접촉을 통해 급속히 유행을 일으키며, 감수성 있는 가족내 접촉자의 ...
본문/내용
수두는 신생아를 포함하여 어느 연령에서나 발생하는 질환으로 호흡기나 직접적인 접촉을 통해 급속히 유행을 일으키며, 감수성 있는 가족내 접촉자의 이차적 감염율이 90%라고 보고 하였다1). 이들 중 대부분이 10세 미만이며 3세에서 6세 사이에 가장 큰 유병율을 가진다고 하였고2,3) 10세 미만의 어린이 90%이상에서 이환 되어질 뿐아니라 특히 생후 첫 6개월 동안은 다른 바이러스 감염보다 더 많이 발생된다.
수두 항체는 임신 중 모체로부터 태반을 통해 태아에게 전달 되지만 생후 급격히 감소하여 6개월에서 1년 사이에 이행 항체가 음성을 나타내며4), 본 연구에서도 대조군에서 6개윌에서 1세 사이의 환아 57명 중 이행 항체(transferred antibody)가 음성을 나타낸 경우는 51명으로 89.5%를 차지하였다. 그러나 건강아 뿐만 아니라 면역 결핍성 횐자에서는 높은 이환율과 함께 사망에까지 이르러5), 면역 감수성 환자에서의 심한 수두를 예방하기 위해 varicella-zoster 면역 글로블린을 이용한 수동적인 면역법이 사용되었으나6) 비경제적이고 VZV에 노출된 후에 사용된다는 단점이 있다.
따라서 수두를 예방하기 위해 1974년 일본에서 처음으로 Takahashi 등7)에 의해 Oka strain 수두 생백신(Iive attenuated varicella vaccine)이 생산되었고, 이렇게 개발된 수두 생백신의 안정성과 효과를 입증하기 위해 일본을 비롯한 많은 나라에서 활발히 연구가 진행되어 왔으며 주로 백혈병과 다른 악성 종양을 가진 환아를 대상으로 먼저 예방 접종이 실시 되었다.일본에서 1975년 부터 1983년 까지 완해(remission)된 백혈병 환자 330 명을 대상으로 …
따라서 수두를 예방하기 위해 1974년 일본에서 처음으로 Takahashi 등7)에 의해 Oka strain 수두 생백신(Iive attenuated varicella vaccine)이 …
따라서 수두를 예방하기 위해 1974년 일본에서 처음으로 Takahashi 등7)에 의해 Oka strain 수두 생백신(Iive attenuated varicella vaccine)이 …
참고문헌
1) Ross AH, Lencher E, Reitman G: Modification of chickenpox in family contacts by administration of gamma globulin. N Engl J Med 267:369-376, 1962
2) Rivers TM, Eldridge LA: Relation of varicella to herpes zoster. I, Statistical observations.Ⅱ (1929), Clinical and experimental observations. J Exp Med 49:899-917, 1929
3) Gordon JE: Chickenpox: An epidemiologic review. Am J Med Sci 244:362-38Q 1962
4) Gershon AA, Raker R, Steinberg S, Topf-Olstein B, Drnsin LM: Antibody to varicella-zoster virus in parturients woman and their offspring during the first year of life. Pediatrics 692-696, 1976
5) Feldman S, Hughes WT, Danial CB: Varicella in children with cancer: Seventy-seven cases. Pediatrics 80:388-397 1975
6) Zala JA, Levin MJ, Freblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio HA, LiGore J: Evaluation of varicella-zoster immunoglobulin: Protection of immunosuppressed children after household exposure to varicella. J Infec Dis 147:737-742, 1983
7) Takahashi M: Current status and prospects of live varicella vaccin. Vaccine 10:1007-1014, 1992
8) Takanashi M, Kanniya H, Baba K, Asana Y, Ozaki T, Horiuchi K: Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J 61:61-67, 1985
9) Gershon AA, Steinberg SP, Gelb L, Galasso C, Borkowski W, LsRussa P, Ferrera A, MAID: Live varicella vaccine: Efficacy for children with leukemia in remission. J Am Med Assoc 252:355-362, 1984
10) Gershon AA, LaRUssa P, Steinberg SP: Live attenuated varicella vaccine: Current status and future uses. Sem Ped Intec Dis 2:171-178, 1991
11) Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S: Varicella vaccine: The american experience. J Inf Dis 166:63-08, 1992
12) Arbeter AM, Granowetter L, Gelser C, Waugh JE: Administration of live varicella vaccine to chidren with leukemia Pediatrics 85:338-344, 1990
13) Brunell PA, Shehab Z, Gelser C, Waugh JE: Administration of live varicella vaccine to children with leuke- mia. Lancet 11:1069-1073, 1982
14) Srabstein JC, Morris N, Larke B, Lesa DJ, Castelino BB, Sum E: Is there a congenital varicella syndrome?. J Pediatr 84:239-243, 1974
15) Gershon AA, Steinberg S, LaRussa p: Rapid detection of immunity to varicella by latex agglutination. Ped Res 31:162A, 1991
16) Heidl M, Scholz H: Varicella vaccination Pediatrie and Grenrgebiete 29:31-36, 1990
17) Gershon AA: Human immune responses to live attenuated varicella vaccine. Reviews of Inf Dis 13:957-959, 1991
18)Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S: Life threatening complications varicella. Am J Dis Child 135:896-899, 1981
19) Ozaki T, Matsui T, Ichikawa T: Clinical trial of the OKA strain of live attenuated varicella vaccine on heal thy children. Biken J 2739-42, 1984
20) Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, Zelson CM, Proctor RA, Platkin SA: Varicella vaccine trials in healty children. AJDC 138:434-438,1984
21) White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, Provost PJ, Ellis RW, Gerety RJ, Calan dra GB: Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989. Pediatrics 87:604-610, 1991
22) Weibel RE, Neff B, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB: Live attenuated varicella virus vaccine: Efficacy trial in healthy children. N Engl J Med 310:1409-1415,1984
23) Arbeter AM, Starr SE, Plotkin SA: Varicella vaccine studies in healthy children and adults. Pediatrics 78:748-756, 1986
24) Asano Y, Albrecht P, Vujcic LK, Quinnan GV, Kawakatni K, Takahashi M: Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics 72:291-294, 1983
25) Asano Y, Nagal T, Miyata T, Yataki T, Ito S, Yamanishi K, Takahashi M: Long-term protec tive immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 75:667-671, 1985
26) Johnson C, Rome L, Stancin T, Kumar M:
Humonal immunity and clinical reinfections follwing varicella vaccine in healthy children Pediatrics 84:418-421, 1989
27) Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton OM, Neff BJ, Provost PJ, Watson BA, Stair SE, Plotkin SA: Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow studies.Vaccine 9:643-647, 1991
28) Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, Arvin AM: Lack of transmission of the live attenuated varicella viccine to immunocompromised children after immunization of their siblings. Pediatrics 87:166-170, 1991
29) Takahashi M, Asano Y, Karniya H, Baha K, Yamanishi K: Prevention and treatment of vancella zoster virus, presented at the International conference on human herpes virus, Emory University, March 20, 1980
30) White CJ: Varicella vaccine reflux. Reply. Pediatrics 89:354, 1992
31) Feldman S, Hughes WT, Kim HY: Herpes zoster in children with cancer. Am J Dis Child 126:178-184, 1973
32) Hardy I, Gershon AA, Steinberg SP, LaRuss p: The incidence of zoster after immunization with live attenuated varicella vaccine. New Eng J Med 325:1545-1550,1991
33) Lawrence R, Gershon A, Holzman R, Steinberg S, NIAID: The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med 318:543-548, 1988
34) Feldman S, Lott L: Varicella in children with cancer. Impact of antivinal therapy and prophylaxis, Pediatrics 80:465-472, 1987
35) Gershon AA, Steinberg SP, National Institude of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group: Live attenuated varicella vaccine: Protection in healty adults compared with leukemic children. J Intect Dis 161:661-666, 1990
36) Russell AS, Maini RA, Bailey M, Dumone DC: Cell mediated immunity to varicella zoster antigen in acute herpes zoster. Clin Exp Immunol 14181-185, 1973
37) uckdeshel JC, Schimoff SC, Smyth AC, Mardiney MR: Herpes zoster and impaired cell associated immunity to the varicella zoster virus in patients with Hodgkin`s disease. Am J Med 62:77-85,1977
38) 안효섭, 김중곤: 약독화된 생수두 백신 접종에 따른 급성 립프구성 백혈병 환아에 서의 면역학적 반응, 소아과 34:1255-1259, 1991
39) Schur PH: IgG subclass-a review. Ann Allergy 58:89-96, 1987
40) Morrell A, Roth-Wicky B, Skvaril F: Immunoglobulin G subclass restriction of antibodies against hepatitis B surface antigen. Infect Immunol 39:565-568, 1983
41) Linde GA: Subclass distribution of rubella virus specific immunoglobulin G. J Clin Microbiol 13:393-396, 1985
42) Coleman RM, Nahinias AJ, Williams SC: IgG subclass antibody to herpes simplex virus. J Intect Dis 151:929-936, 1985
43) Linde GA, Hammarstrom L, Persson M: Virus specific antibody activity of different subclass of immunoglobulin G and A in cytomegalovirus infections, Infect Immunol 42:237-244, 1983
44) Wager DK, Graham BS, Wright PF: Serum immunoglobulin G antibody subclass responses to respiratory syncitial virus F and G glycoproteins after primary infection. J Clin Microbiol 24:304-3O6, 1986
2) Rivers TM, Eldridge LA: Relation of varicella to herpes zoster. I, Statistical observations.Ⅱ (1929), Clinical and experimental observations. J Exp Med 49:899-917, 1929
3) Gordon JE: Chickenpox: An epidemiologic review. Am J Med Sci 244:362-38Q 1962
4) Gershon AA, Raker R, Steinberg S, Topf-Olstein B, Drnsin LM: Antibody to varicella-zoster virus in parturients woman and their offspring during the first year of life. Pediatrics 692-696, 1976
5) Feldman S, Hughes WT, Danial CB: Varicella in children with cancer: Seventy-seven cases. Pediatrics 80:388-397 1975
6) Zala JA, Levin MJ, Freblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio HA, LiGore J: Evaluation of varicella-zoster immunoglobulin: Protection of immunosuppressed children after household exposure to varicella. J Infec Dis 147:737-742, 1983
7) Takahashi M: Current status and prospects of live varicella vaccin. Vaccine 10:1007-1014, 1992
8) Takanashi M, Kanniya H, Baba K, Asana Y, Ozaki T, Horiuchi K: Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J 61:61-67, 1985
9) Gershon AA, Steinberg SP, Gelb L, Galasso C, Borkowski W, LsRussa P, Ferrera A, MAID: Live varicella vaccine: Efficacy for children with leukemia in remission. J Am Med Assoc 252:355-362, 1984
10) Gershon AA, LaRUssa P, Steinberg SP: Live attenuated varicella vaccine: Current status and future uses. Sem Ped Intec Dis 2:171-178, 1991
11) Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S: Varicella vaccine: The american experience. J Inf Dis 166:63-08, 1992
12) Arbeter AM, Granowetter L, Gelser C, Waugh JE: Administration of live varicella vaccine to chidren with leukemia Pediatrics 85:338-344, 1990
13) Brunell PA, Shehab Z, Gelser C, Waugh JE: Administration of live varicella vaccine to children with leuke- mia. Lancet 11:1069-1073, 1982
14) Srabstein JC, Morris N, Larke B, Lesa DJ, Castelino BB, Sum E: Is there a congenital varicella syndrome?. J Pediatr 84:239-243, 1974
15) Gershon AA, Steinberg S, LaRussa p: Rapid detection of immunity to varicella by latex agglutination. Ped Res 31:162A, 1991
16) Heidl M, Scholz H: Varicella vaccination Pediatrie and Grenrgebiete 29:31-36, 1990
17) Gershon AA: Human immune responses to live attenuated varicella vaccine. Reviews of Inf Dis 13:957-959, 1991
18)Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S: Life threatening complications varicella. Am J Dis Child 135:896-899, 1981
19) Ozaki T, Matsui T, Ichikawa T: Clinical trial of the OKA strain of live attenuated varicella vaccine on heal thy children. Biken J 2739-42, 1984
20) Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, Zelson CM, Proctor RA, Platkin SA: Varicella vaccine trials in healty children. AJDC 138:434-438,1984
21) White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, Provost PJ, Ellis RW, Gerety RJ, Calan dra GB: Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989. Pediatrics 87:604-610, 1991
22) Weibel RE, Neff B, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB: Live attenuated varicella virus vaccine: Efficacy trial in healthy children. N Engl J Med 310:1409-1415,1984
23) Arbeter AM, Starr SE, Plotkin SA: Varicella vaccine studies in healthy children and adults. Pediatrics 78:748-756, 1986
24) Asano Y, Albrecht P, Vujcic LK, Quinnan GV, Kawakatni K, Takahashi M: Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics 72:291-294, 1983
25) Asano Y, Nagal T, Miyata T, Yataki T, Ito S, Yamanishi K, Takahashi M: Long-term protec tive immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 75:667-671, 1985
26) Johnson C, Rome L, Stancin T, Kumar M:
Humonal immunity and clinical reinfections follwing varicella vaccine in healthy children Pediatrics 84:418-421, 1989
27) Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton OM, Neff BJ, Provost PJ, Watson BA, Stair SE, Plotkin SA: Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow studies.Vaccine 9:643-647, 1991
28) Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, Arvin AM: Lack of transmission of the live attenuated varicella viccine to immunocompromised children after immunization of their siblings. Pediatrics 87:166-170, 1991
29) Takahashi M, Asano Y, Karniya H, Baha K, Yamanishi K: Prevention and treatment of vancella zoster virus, presented at the International conference on human herpes virus, Emory University, March 20, 1980
30) White CJ: Varicella vaccine reflux. Reply. Pediatrics 89:354, 1992
31) Feldman S, Hughes WT, Kim HY: Herpes zoster in children with cancer. Am J Dis Child 126:178-184, 1973
32) Hardy I, Gershon AA, Steinberg SP, LaRuss p: The incidence of zoster after immunization with live attenuated varicella vaccine. New Eng J Med 325:1545-1550,1991
33) Lawrence R, Gershon A, Holzman R, Steinberg S, NIAID: The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med 318:543-548, 1988
34) Feldman S, Lott L: Varicella in children with cancer. Impact of antivinal therapy and prophylaxis, Pediatrics 80:465-472, 1987
35) Gershon AA, Steinberg SP, National Institude of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group: Live attenuated varicella vaccine: Protection in healty adults compared with leukemic children. J Intect Dis 161:661-666, 1990
36) Russell AS, Maini RA, Bailey M, Dumone DC: Cell mediated immunity to varicella zoster antigen in acute herpes zoster. Clin Exp Immunol 14181-185, 1973
37) uckdeshel JC, Schimoff SC, Smyth AC, Mardiney MR: Herpes zoster and impaired cell associated immunity to the varicella zoster virus in patients with Hodgkin`s disease. Am J Med 62:77-85,1977
38) 안효섭, 김중곤: 약독화된 생수두 백신 접종에 따른 급성 립프구성 백혈병 환아에 서의 면역학적 반응, 소아과 34:1255-1259, 1991
39) Schur PH: IgG subclass-a review. Ann Allergy 58:89-96, 1987
40) Morrell A, Roth-Wicky B, Skvaril F: Immunoglobulin G subclass restriction of antibodies against hepatitis B surface antigen. Infect Immunol 39:565-568, 1983
41) Linde GA: Subclass distribution of rubella virus specific immunoglobulin G. J Clin Microbiol 13:393-396, 1985
42) Coleman RM, Nahinias AJ, Williams SC: IgG subclass antibody to herpes simplex virus. J Intect Dis 151:929-936, 1985
43) Linde GA, Hammarstrom L, Persson M: Virus specific antibody activity of different subclass of immunoglobulin G and A in cytomegalovirus infections, Infect Immunol 42:237-244, 1983
44) Wager DK, Graham BS, Wright PF: Serum immunoglobulin G antibody subclass responses to respiratory syncitial virus F and G glycoproteins after primary infection. J Clin Microbiol 24:304-3O6, 1986
| 📝 Regist Info |
|
I D : sypj***** Date : 2014-12-03 FileNo : 16064447 |
Cart  | |
| |